ESD AND OUTCOMES IN BARRETT’S ESOPHAGEAL ADENOCARCINOMA

Abstract

The incidence of Barrettʼs esophageal adenocarcinoma(BEA) is increasing in Europe and the United States. Recently, BEA has been gradually increasing in Japan. The pathological diagnosis, lesion background(short- or long-segment Barrettʼs esophagus; SSBE or LSBE), associated residual Barrettʼs esophagus(BE), and treatment strategies of these lesions differ between Japan and the West. In Japan, ESD is the mainstay of treatment for BEA, and the majority of cases are SSBE in origin. However, in Europe and the United States, more than half of the patients have LSBE. Furthermore, ablation therapy is recommended for BE itself due to the presence of dysplasia after endoscopic treatment of visible BEA lesions; however, this is not the case in Japan. Herein, we have described the ESD and treatment outcomes based on the changes in the 2022 Esophageal Cancer Treatment Protocol(12th edition) for Barrettʼs esophagus.